Vital Care Express LogoVital Care Express
Health Economics

Danes on GLP-1 drugs took far fewer month-plus sick-leave spells. The salary math is real, but it leaves out the price of the drugs.

July 22, 2026
#GLP-1#sick leave#workforce productivity#economic impact
Danes on GLP-1 drugs took far fewer month-plus sick-leave spells. The salary math is real, but it leaves out the price of the drugs.

The short version

  • Workers on GLP-1 medications in Denmark took 17% fewer long-term sick-leave spells than comparable peers, counting absences longer than 30 days.
  • That works out to salary savings of up to 1.5% per employee, roughly $866 on average.
  • The analysis leaned on Denmark’s linked worker-level and prescription data and came out this month from the National Bureau of Economic Research.
  • The catch: it never counts what the drugs cost. So the savings are real but only one side of the ledger.

What the study actually found

Denmark keeps unusually detailed records that tie employment history to prescription history, which lets researchers see who took what and how much work they missed. A new NBER analysis used exactly that. It found that workers who received a GLP-1 medication took 17% less long-term sick leave, defined as absences running past 30 days, than workers who did not.

Put in money, that is up to a 1.5% cut in what an individual costs in salary, averaging about $866 per worker. Fewer long stretches out of the office means fewer stretches of paying someone who cannot work.

Why a diabetes and obesity drug shows up in the sick-leave data

GLP-1 drugs, formally glucagon-like peptide-1 receptor agonists, are prescribed for type 2 diabetes and obesity. They steady blood sugar and blunt appetite, which tends to bring weight down and, over time, improves cardiovascular health. Picture the pathway as a valve that eases both appetite and blood-sugar spikes so the system is not constantly overloaded.

The link to work is not mysterious. Healthier people, on average, need fewer long recoveries. Better-managed diabetes and less obesity mean fewer of the complications that put someone out for a month or more.

Who this helps, and by how much

The gains spread across three groups. Workers keep more of their pay, since fewer month-plus absences mean less time off full wages, the $866 figure above. Employers carry fewer extended leaves to fund. And in a system like Denmark’s, the government saves on the state-paid portion of long absences, because fewer workers cross that 30-day line at all.

Scale it up and the appeal is obvious: a workforce with a lot of diabetes and obesity is a workforce with a lot of potential long absences, and a 17% dent in those is not trivial.

How much to make of it

Here is where the headline needs a firm hand. Three things pull the $866 back toward “partial picture.”

First, it is Danish data, and Denmark splits sick-leave costs between employer-paid short-term and state-paid long-term leave in a way most countries do not. That structure shapes the result. Second, and most important, the analysis leaves out the price of the GLP-1 medicines entirely, and those are expensive, so the true net balance is unknown. Third, it only looked at long-term leave. Short absences and presenteeism, meaning people who show up but work at half capacity while unwell, were never measured.

None of that makes the 17% fake. It makes it incomplete.

What would settle it

The authors float the idea that this could matter for the U.S. labor market, which has far thinner sick-leave protections, but there is no U.S. data yet. To turn this from a suggestive result into a decision-grade one, future work needs to:

  • Rerun the analysis in countries with different sick-leave structures.
  • Measure short-term absence and presenteeism, not just the long spells.
  • Put drug acquisition costs into the equation so the net, not just the upside, is visible.

Until then, an employer or policymaker looking at this should treat the $866 as the ceiling of the benefit, not the bottom line, and weigh it against local wage costs and their own leave rules.

Sources

Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.

Frequently Asked Questions

What are GLP-1 drugs used for?

They are prescribed for type 2 diabetes and obesity. They help steady blood sugar and, for many people, lead to weight loss. The brand names people recognize, like Ozempic and Wegovy, are in this class.

Does the study count the cost of the GLP-1 drugs themselves?

No, and this is the biggest hole in the headline. The analysis measures the savings from less sick leave but never subtracts what the medicines cost, which can run to hundreds of dollars a month. So the $866 figure is a benefit with the price tag left off the other side of the ledger.

Would this 17% drop hold up outside Denmark?

Unclear. The authors think it might carry over to other job markets, but they are cautious, because Denmark's system for paying sick leave is unusual. Countries where employers or workers absorb absence costs differently could see a very different number.

What exactly does "17% less long-term sick leave" mean here?

Long-term leave in the study means an absence lasting more than 30 days. Workers who took a GLP-1 drug had 17% fewer of those long spells than similar workers who did not. It does not measure the short one or two-day absences, which were left out.

Should an employer read this as a reason to cover GLP-1 drugs?

It is a data point, not a settled case. The absence savings look real, but until someone puts the drug cost, the short-term absences, and working-while-sick into the same equation, an employer only has half the picture.

AI Assisted